Loading clinical trials...

The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III) | Clinical Trials | Clareo Health

COMPLETEDNA

The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

NCT00002048•Glaxo Wellcome

View on ClinicalTrials.gov

Summary

To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) in HIV-infected adult patients without clinical manifestations of disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients.

Eligibility

Age

13 - No limit years

Sex

ALL

Healthy Volunteers

Exclusion Criteria

•Co-existing Condition:
•Patients with the following are excluded:
•Prior history of a malignancy other than cutaneous basal cell or cervical carcinomas.
•Other significant, chronic underlying medical illness which would impair study completion.
•Liver dysfunction as demonstrated by lab results.
•Laboratory evidence of compromised bone marrow function.
•Concurrent Medication:
•Excluded:
•Any other experimental agents.
•Any probenecid-containing product.
+26 more criteria

Locations (22)

LaJolla Veterans Administration Med Ctr

La Jolla, California, United States

AIDS Clinical Trials Group

San Diego, California, United States

Georgetown Univ Med Ctr

Washington D.C., District of Columbia, United States

Univ of Miami School of Medicine

Miami, Florida, United States

Univ of South Florida

Tampa, Florida, United States

Emory Univ School of Medicine

Atlanta, Georgia, United States

Univ of New Mexico Hlth Sciences Ctr / Dept of Med

Albuquerque, New Mexico, United States

Northshore Hosp / Cornell Univ

Manhasset, New York, United States

Nalle Clinic

Charlotte, North Carolina, United States

Bowman Gray School of Medicine / North Carolina Baptist Hosp

Winston-Salem, North Carolina, United States

Key Dates

Last Updated

June 24, 2005

Conditions

Lymphatic DiseaseHIV Infections

Interventions

Zidovudine

DRUG

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2005Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

Exclusion Criteria

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Skeletal Muscle Energetics and Fatiguability in Older Individuals

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Comprehensive HIV and Harm Prevention Via Telehealth

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706